This project aims at developing a universal “plug-and-play” liver-on-chip platform mimicking the major events occurring in the liver sinusoid – barrier/sieving effect resulting from the specific fenestration of liver sinusoidal endothelial cells (LSECs), biotransformation and metabolism in the hepatocytes themselves – in order to predict the hepatoxicity of drugs.
What we bring to the partnership
In this projet, HCS Pharma coordinates a workpackage aiming at benchmarking and validating the liver biochip and LSECs-hepatocytes coupled model, by evaluating and comparing the effects of known substances. HCS Pharma will also provide BIOMIMESYS® as a biological matrix for the culture of hepatocytes in the chips.
List of partners
- Laboratoire BMBI – UMR CNRS 7338 – Université de Technologie de Compiègne
- UMI CNRS 2820 LIMMS
- Institut d’Électronique de Microélectronique et de Nanotechnologie (IEMN) – UMR 8520
- HCS Pharma